Immatics N.V. (NASDAQ: IMTXW) is a clinical-stage biopharmaceutical company dedicated to the development of T-cell receptor (TCR)–based immunotherapies for cancer. Utilizing its proprietary XPRESIDENT antigen discovery platform, the company identifies tumor-associated peptides and matches them with high-affinity TCRs to create redirected T cells capable of recognizing and eliminating cancer cells. Immatics’ approach targets both solid tumors and hematologic malignancies, aiming to improve patient outcomes where conventional treatments have limited efficacy.
The company’s most advanced programs, including IMC-F106C and IMC-F212C, are in clinical development for patients with advanced solid tumors. Immatics is exploring these candidates as monotherapies as well as in combination regimens, seeking to enhance therapeutic potency and broaden the potential patient population. In parallel, a suite of preclinical assets is advancing through discovery to expand the pipeline and address additional cancer indications.
Founded in 2000, Immatics is headquartered in Tübingen, Germany, with research facilities in Munich and a U.S. presence in Cambridge, Massachusetts. The company conducts multi-regional clinical trials across Europe and North America and collaborates with leading academic institutions, biotechnology firms, and pharmaceutical partners. This global footprint supports seamless progression from discovery through regulatory review and commercialization.
Led by Chief Executive Officer Harpreet Singh, Immatics is guided by a management team with deep expertise in biotechnology, clinical development, and global operations. With a robust intellectual property portfolio encompassing hundreds of patents and applications, the company is well positioned to deliver innovative cancer immunotherapies and address critical unmet medical needs.
AI Generated. May Contain Errors.
